A high-dose quadrivalent influenza vaccine (Fluzone High-Dose Quadrivalent) is available on the private market in Australia in 2022 for adults aged 60 years and older. It contains four times the antigen content of standard influenza vaccines and has higher effectiveness in people aged 65 years and older while maintaining an acceptable safety profile. It also has comparable effectiveness and safety to the adjuvanted influenza vaccine in this age group.
Influenza is a seasonal infectious disease that usually circulates in the colder months, between April and October in Australia. Most people recover from influenza without serious illness; however, older adults, young children, pregnant women and people with certain chronic medical conditions are at higher risk of developing serious complications.1 Influenza-associated mortality rates are highest among adults aged 65 years and older.1,2